Long-term follow-up of the first in human post-transcriptional genetic silencing of BCL11A in sickle cell disease in a phase 1 pilot and feasibility trialErica B. Esrick, David A. Williams, Leslie Lehmann et al.|Blood|2025Cited by 1
Highly efficient collection and manufacture of autologous HSC gene therapy cell product for patients with sickle cell disease using a lentiviral vector containing a shmir targeting BCL11aJohn Manis, David A. Williams, Mary Horowitz et al.|Blood|2025Cited by 1